中老年男性慢性阻塞性肺病合并肺癌患者的临床特征分析及数学预测模型的建立
Analysis of Clinical Features and Establishment of Mathematical Prediction Model in Middle-Aged and Elderly Male Patients with Chronic Obstructive Pulmonary Disease Complicated with Lung Cancer
DOI: 10.12677/acm.2024.143912, PDF,   
作者: 程玮媛:青岛大学医学部青岛市市立医院,山东 青岛;王晓燕:青岛市市立医院国际门诊,山东 青岛;唐华平*:青岛市市立医院呼吸与危重症医学科,山东 青岛
关键词: 慢性阻塞性肺病肺癌临床特征预测模型Chronic Obstructive Pulmonary Disease Lung Cancer Clinical Features Prediction Model
摘要: 目的:分析慢性阻塞性肺病(Chronic Obstructive Pulmonary Disease, COPD)合并肺癌患者的临床资料特征,并建立其风险预测模型。方法:回顾性收集并分析79例COPD合并肺癌患者(共病组)和150例COPD组的临床资料,包括:年龄、体重指数(Body Mass Index, BMI)、吸烟指数、相关实验室检验指标及肺癌病理诊断结果等;使用SPSS 27.0对数据进行单因素及多因素Logistic回归分析筛选出独立危险因素,建立数学预测模型,通过R软件进行模型内部验证及评价。结果:该数学模型由三项危险因素组成,分别为血沉(ESR)、NLR (中性粒细胞计数与淋巴细胞计数比值)、碱性磷酸酶(ALP)。ROC曲线下面积为0.913 (95% CI, 0.844~0.982, P < 0.05),采用Bootstrap方法进行模型内部验证,抽样次数设置为1000次,在内部验证集,本模型的敏感度为0.828,特异度为0.861,C指数为0.913 (95%置信区间0.839~0.971),此外校准曲线代表了该模型良好的性能,临床决策曲线(DCA决策曲线)显示该模型可以做出有价值的判断。结论:基于慢性阻塞性肺病合并肺癌的3项危险因素建立的预测模型有较好的预测能力,对于70岁以下男性COPD患者中肺癌的高危人群筛查有一定指导价值。
Abstract: Objective: To analyze the clinical data characteristics of chronic obstructive pulmonary disease (COPD) combined with lung cancer, and to establish a risk prediction model for the patients. Methods: Clinical data of 79 patients with COPD complicated with lung cancer (comorbidity group) and 150 patients with COPD were retrospectively collected and analyzed, including age, body mass index (BMI), smoking index, relevant laboratory test indexes and pathological diagnosis results of lung cancer. SPSS 27.0 was used for single factor and multiple factor Logistic regression analysis to screen out independent risk factors, and a mathematical prediction model was established. R software was used for internal verification and evaluation of the model. Results: The mathematical model was composed of three risk factors, namely erythrocyte sedimentation rate (ESR), NLR (ratio of neutrophil count to lymphocyte count) and alkaline phosphatase. The area under ROC curve was 0.913 (95% CI, 0.844~0.982, P < 0.05). Bootstrap method was used for internal verification of the model, and the sampling times were set to 1000 times. The sensitivity and specificity of this model were 0.828 and 0.861. The C-index was 0.913 (95% confidence interval 0.839~0.971), and the calibration curve represented a good performance of the model, and the clinical decision curve (DCA decision curve) showed that the model could make valuable judgments. Conclusion: The prediction model based on three risk factors of COPD combined with lung cancer has a good predictive ability, and has a certain guiding value for screening high-risk groups of lung cancer in male COPD patients under 70 years old.
文章引用:程玮媛, 王晓燕, 唐华平. 中老年男性慢性阻塞性肺病合并肺癌患者的临床特征分析及数学预测模型的建立[J]. 临床医学进展, 2024, 14(3): 1813-1823. https://doi.org/10.12677/acm.2024.143912

参考文献

[1] Kahnert, K., Jörres, R.A., Behr, J. and Welte, T. (2023) The Diagnosis and Treatment of COPD and Its Comorbidities. DÄ International, 120, 434-444. [Google Scholar] [CrossRef
[2] Guo, P., Li, R., Piao, T.H., Wang, C.L., et al. (2022) Pathological Mechanism and Targeted Drugs of COPD. The International Journal of Chronic Obstructive Pulmonary Disease, 17, 1565-1575. [Google Scholar] [CrossRef
[3] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[4] 罗晨阳, 何志文. 慢性阻塞性肺疾病与合并症[J]. 结核与肺部疾病杂志, 2023, 4(5): 407-412.
[5] Forder, A., Zhuang, R., Souza, V.G.P., et al. (2023) Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer. International Journal of Molecular Sciences, 24, Article No. 2859. [Google Scholar] [CrossRef] [PubMed]
[6] Qi, C., Sun, S.-W. and Xiong, X.-Z. (2022) From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis. The International Journal of Chronic Obstructive Pulmonary Disease, 17, 2603-2621. [Google Scholar] [CrossRef
[7] Sekine, Y., Hata, A., Hiroshima, K., et al. (2014) Lung Carcinogenesis from Chronic Obstructive Pulmonary Disease: Characteristics of Lung Cancer from COPD and Contribution of Signal Transducers and Lung Stem Cells in the Inflammatory Microenvironment. General Thoracic and Cardiovascular Surgery, 62, 415-421. [Google Scholar] [CrossRef] [PubMed]
[8] Uliński, R., Kwiecień, I. and Domagała-Kulawik, J. (2022) Lung Cancer in the Course of COPD-Emerging Problems Today. Cancers, 14, Article No. 3819. [Google Scholar] [CrossRef] [PubMed]
[9] Siegfried, J.M. (2022) Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung Disease. Endocrinology, 163, bqab254. [Google Scholar] [CrossRef] [PubMed]
[10] Deng, C., Zhang, N., Wang, Y., Jiang, S., et al. (2019) High Systemic Immune-Inflammation Index Predicts Poor Prognosis in Advanced Lung Adenocarcinoma Patients Treated with EGFR-TKIs. Medicine (Baltimore), 98, e16875. [Google Scholar] [CrossRef
[11] Li, Y. and Hecht, S.S. (2022) Carcinogenic Components of Tobacco and Tobacco Smoke: A 2022 Update. Food and Chemical Toxicology, 165, Article ID: 113179. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, M., Zhang, Y., Xu, M., Zhang, H., et al. (2019) Roles of TRPA1 and TRPV1 in Cigarette Smoke-Induced Airway Epithelial Cell Injury Model. Free Radical Biology and Medicine, 134, 229-238. [Google Scholar] [CrossRef] [PubMed]
[13] Xu, L.M., Zhou, L., Yan, C. and Li, L. (2022) Emerging Role of N6-Methyladenosine RNA Methylation in Lung Diseases. Experimental Biology and Medicine, 247, 1862-1872. [Google Scholar] [CrossRef] [PubMed]
[14] Nader, C.P., Cidem, A., Verrills, N.M. and Ammit, A.J. (2019) Protein Phosphatase 2A (PP2A): A Key Phosphatase in the Progression of Chronic Obstructive Pulmonary Disease (COPD) to Lung Cancer. Respiratory Research, 20, 222. [Google Scholar] [CrossRef] [PubMed]
[15] Rogers, L.K. and Cismowski, M.J. (2018) Oxidative Stress in the Lung—The Essential Paradox. Current Opinion in Toxicology, 7, 37-43. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, I.A., Relan, V., Wright, C.M. et al. (2011) Common Pathogenic Mechanisms and Pathways in the Development of COPD and Lung Cancer. Expert Opinion on Therapeutic Targets, 15, 439-456. [Google Scholar] [CrossRef] [PubMed]
[17] Kornum, J.B., Farkas, D.K., Severinsen, M.T., et al. (2019) Cancer Risk and Prognosis after a Hospital Contact for an Elevated Erythrocyte Sedimentation Rate. Cancer Epidemiology, Biomarkers & Prevention, 28, 225-232. [Google Scholar] [CrossRef
[18] Xu, J., Cheng, F., Li, Y., Zhang, J., et al. (2021) Erythrocyte Sedimentation Rate Combined with the Probe-to-Bone Test for Fast and Early Diagnosis of Diabetic Foot Osteomyelitis. The International Journal of Lower Extremity Wounds, 20, 227-231. [Google Scholar] [CrossRef] [PubMed]
[19] Akkiz, H., Carr, B.I., Bag, H.G., Karaoğullarından, Ü., et al. (2021) Serum Levels of Inflammatory Markers CRP, ESR and Albumin in Relation to Survival for Patients with Hepatocellular Carcinoma. International Journal of Clinical Practice, 75, e13593. [Google Scholar] [CrossRef] [PubMed]
[20] Litao, M.K. and Kamat, D. (2014) Erythrocyte Sedimentation Rate and C-Reactive Protein: How Best to Use Them in Clinical Practice. Pediatric Annals, 43, 417-420. [Google Scholar] [CrossRef] [PubMed]
[21] Tekneci, A.K., Akçam, T.İ., Kavurmacı, Ö., Ergönül, A.G., et al. (2022) Relationship between Survival and Erythrocyte Sedimentation Rate in Patients Operated for Lung Cancer. Türk Göğüs Kalp Damar Cerrahisi Dergisi, 30, 381-388. [Google Scholar] [CrossRef] [PubMed]
[22] Platini, H., Ferdinand, E., Kohar, K., Prayogo, S.A., et al. (2022) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Kaunas), 58, Article No. 1069. [Google Scholar] [CrossRef] [PubMed]
[23] Russo, A., Russano, M., Franchina, T., Migliorino, M.R., et al. (2020) Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Advances in Therapy, 37, 1145-1155. [Google Scholar] [CrossRef] [PubMed]
[24] Nøst, T.H., Alcala, K., Urbarova, I., Byrne, K.S., et al. (2021) Systemic Inflammation Markers and Cancer Incidence in the UK Biobank. European Journal of Epidemiology, 36, 841-848. [Google Scholar] [CrossRef] [PubMed]
[25] Xiong, S., Dong, L. and Cheng, L. (2021) Neutrophils in Cancer Carcinogenesis and Metastasis. Journal of Hematology & Oncology, 14, 173. [Google Scholar] [CrossRef] [PubMed]
[26] Tolle, F., Umansky, V., Utikal, J., Kreis, S., et al. (2021) Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies? International Journal of Molecular Sciences, 22, Article No. 6744. [Google Scholar] [CrossRef] [PubMed]
[27] Wolf, N.K., Kissiov, D.U. and Raulet, D.H. (2023) Roles of Natural Killer Cells in Immunity to Cancer, and Applications to Immunotherapy. Nature Reviews Immunology, 23, 90-105. [Google Scholar] [CrossRef] [PubMed]
[28] Lang, J., Zhao, Q., He, Y. and Yu, X. (2018) Bone Turnover Markers and Novel Biomarkers in Lung Cancer Bone Metastases. Biomarkers, 23, 518-526. [Google Scholar] [CrossRef
[29] Du, W., Guan, H., Wan, X., Zhu, Z., et al. (2023) Circulating Liver Function Markers and the Risk of COPD in the UK Biobank. Frontiers in Endocrinology (Lausanne), 14, Article ID: 1121900. [Google Scholar] [CrossRef] [PubMed]